GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Common Stock

LTR Pharma (ASX:LTP) Common Stock : A$10.78 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Common Stock?

LTR Pharma's quarterly common stock increased from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$2.79 Mil) and increased from Jun. 2022 (A$2.79 Mil) to Jun. 2023 (A$10.78 Mil).

LTR Pharma's annual common stock increased from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$2.79 Mil) and increased from Jun. 2022 (A$2.79 Mil) to Jun. 2023 (A$10.78 Mil).


LTR Pharma Common Stock Historical Data

The historical data trend for LTR Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Common Stock Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Common Stock
- 2.79 10.78

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Common Stock - 2.79 10.78

LTR Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


LTR Pharma (ASX:LTP) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines